The Cabilly Saga: New Patent, New Product, New Lawsuits
This article was originally published in The Pink Sheet Daily
Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.
You may also be interested in...
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
With launch just underway of its newly approved lupus drug, HGS is seeing encouraging signs early on from payers.
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.